Skip to main content

GETEC acquires Infrapark Baselland

| News

GETEC acquires Infrapark Baselland


The energy services provider GETEC is acquiring Infrapark Baselland AG and its activities from the chemicals company Clariant. GETEC also intends to acquire Novartis’s facilities in the neighbouring Schweizerhalle, thus boosting the site’s attractiveness.

Clariant, Infrapark Baselland AG and GETEC recently signed the agreement for the planned sale to GETEC, announced a statement from Infrapark Baselland AG. According to the terms, the transaction will be completed by the end of the year.

GETEC is also acquiring Novartis’s production and infrastructure facilities in the Schweizerhalle site. The move signals the creation of a “new and diversified industrial park with economic significance for the entire region”, writes the statement.

“We are very pleased to have found in GETEC an owner for Infrapark Baselland AG, which has the necessary know-how to operate, integrate and develop industrial parks. I am convinced that this step will give the Schweizerhalle location and thus the employees an attractive future perspective,” commented Oliver Kinkel, head of region Europe at Clariant, in the statement.

With GETEC as operator, Schweizerhalle will gain competitiveness as a chemical life science park and create better growth opportunities “for new companies operating on the site”. A first company has already signed to move into the Schweizerhalle in the coming year: the chemicals specialist Van Baerle. Following the sale, Clariant will also remain as a tenant in Infrapark Baselland.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.